You can buy or sell MDCO and other stocks, options, ETFs, and crypto commission-free!
Medicines Company (The) Common Stock, also called Medicines Company, is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. Read More The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.
Parsippany, New Jersey
52 Week High
52 Week Low
Present Performance: The Medicines Company (NASDAQ: MDCO)
The Medicines Company is in the drug manufacturers industry and is part of the healthcare sector. The company CEO is Mark Timney. The Medicines Co is a pharmaceutical company. It provides transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers. The company’s products are Angiomax, Ionsys, Minocin for injection and Orbactiv. Previous Intraday Trading Performance: The MDCO stock showed a previous change of 3.59% with an open at 27.58 and a close of ...
Associated PressMar 13
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from Prior Quarter ~ ~ Corporate Milestones Across Commercial Operations, Clinical and Business Development Provide Critical Growth Opportunities ~ ~ Provides Guidance for 2019 ~ MORRISTOWN, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and ...
Simply Wall StMar 11
Will The Medicines Company’s (NASDAQ:MDCO) Earnings Grow In The Next Couple Of Years?
The latest earnings announcement The Medicines Company (NASDAQ:MDCO) released in December 2018 confirmed that losses became smaller relative to the prior year’s level as a result of recent tailwinds Below is my commentary, albeit very simple and high-level, on how market analysts perceive Medicines’s earnings growth trajectory over the next few years and whether the future looks brighter.
Expected Apr 24, Pre-Market